Bio-Techne Files Preliminary Proxy for $73/Share Merck KGaA Acquisition
TECH sits 67% above its 52-week low of $43.195.
Summary
Bio-Techne filed its preliminary proxy statement for the $73 per share all-cash acquisition by Merck KGaA, detailing the board's unanimous recommendation, the fairness opinion, and the competitive bidding process that led to the deal. The filing sets the stage for a shareholder vote on the $11.3 billion transaction.
Key Events · M&A and Partnerships · TECH
-
Merger Agreement at $73/Share
Bio-Techne entered into a definitive agreement to be acquired by Merck KGaA for $73.00 per share in cash, a 24% premium to the last undisturbed closing price of $58.88 on June 24, 2026. The total transaction value is approximately $11.3 billion.
-
Board Unanimously Recommends Approval
The Bio-Techne board unanimously determined the merger is in the best interests of shareholders, citing the certainty of cash consideration, the elimination of stand-alone risks, and the fairness opinion from Goldman Sachs.
-
Competitive Bidding Process
The proxy reveals a months-long process involving multiple bidders, with Merck KGaA increasing its offer from an initial $65 to $73 per share. Party B submitted a competing bid at $71 per share before pausing its pursuit.
-
Goldman Sachs Fairness Opinion
Goldman Sachs rendered a fairness opinion, supported by discounted cash flow analysis ($58-$72 per share), selected transactions analysis ($49-$67 per share), and premiums paid analysis ($67-$86 per share).
Analysis · TECH · Life Sciences
The preliminary proxy statement from Bio-Techne delivers the first in-depth account of the $73 per share all-cash acquisition by Merck KGaA, covering the board's rationale, Goldman Sachs' fairness opinion, management projections, and the negotiation background. It reveals that the $73 offer—a 24% premium to the undisturbed price—emerged from a competitive process with multiple bidders. The board unanimously recommends shareholders vote FOR the merger, emphasizing the certainty of cash consideration and the removal of stand-alone risks. The proxy also details substantial golden parachute payments for executives, with CEO Kim Kelderman potentially receiving over $52 million in merger-related compensation. The shareholder vote stands as the next critical milestone, with the meeting date yet to be set.
At the time of this filing, TECH was trading at $72.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $43.20 to $72.39. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.